CoChat

The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition

Open access
Guy, Anne, Brown, Marion, Lewis, Stevie, Horowitz, Mark · 2020 · Therapeutic Advances in Psychopharmacology

The DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index; 31 of the 81 sources its claims cite were checked for support.

Abstract

Background: Stopping antidepressants commonly causes withdrawal symptoms, which can be severe and long-lasting. National Institute for Health and Care Excellence (NICE) guidance has been recently updated to reflect this; however, for many years withdrawal (discontinuation) symptoms were characterised as ‘usually mild and self-limiting over a week’. Consequently, withdrawal symptoms might have been misdiagnosed as relapse of an underlying condition, or new onset of another medical illness, but this has never been studied. Method: This paper outlines the themes emerging from 158 respondents to an open invitation to describe the experience of prescribed psychotropic medication withdrawal for petitions sent to British parliaments. The accounts include polypharmacy (mostly antidepressants and benzodiazepines) but we focus on antidepressants because of the relative lack of awareness about their withdrawal effects compared with benzodiazepines. Mixed method analysis was used, including a ‘lean thinking’ approach to evaluate common failure points. Results: The themes identified include: a lack of information given to patients about the risk of antidepressant withdrawal; doctors failing to recognise the symptoms of withdrawal; doctors being poorly informed about the best method of tapering prescribed medications; patients being diagnosed with relapse of the underlying condition or medical illnesses other than withdrawal; patients seeking advice outside of mainstream healthcare, including from online forums; and significant effects on functioning for those experiencing withdrawal. Discussion: Several points for improvement emerge: the need for updating of guidelines to help prescribers recognise antidepressant withdrawal symptoms and to improve informed consent processes; greater availability of non-pharmacological options for managing distress; greater availability of best practice for tapering medications such as antidepressants; and the vital importance of patient feedback. Although the patients captured in this analysis might represent medication withdrawal experiences that are more severe than average, they highlight the current inadequacy of health care systems to recognise and manage prescribed drug withdrawal, and patient feedback in general.

Overview

CoChat Summary

TL;DR

This qualitative analysis of 158 patient accounts submitted to Scottish and Welsh parliamentary petitions describes antidepressant withdrawal as frequently unrecognised by clinicians, leading to misdiagnosis as relapse or new medical conditions and to patients seeking help outside mainstream care. Respondents reported lack of information about withdrawal, severe symptoms, and substantial functional harms.

Key findings

  • In 158 respondents, 67% were initially prescribed antidepressants and 24% benzodiazepines/z-drugs; 97% were offered a prescription at initial consultation, 5% talking therapy, and 0.6% lifestyle advice.
  • Among those reporting, 46% were not warned about side effects and 47% were not warned about withdrawal; 0% reported being warned about either. After dose reduction, 82% reported new symptoms and 91% described them as severe.
  • 47% said doctors did not recognise symptoms as withdrawal (12% did); 25% were diagnosed with a new medical condition such as medically unexplained symptoms; 42% found doctors unhelpful and inaccurate, and 1% found them helpful. 51% sought help from unregulated, non-medical sources, most often online.
  • Withdrawal impacts included 47% job loss, 82% loss of health and wellbeing, 35% financial hardship, and an average of 15 years of life impacted.

Methods

  • Mixed qualitative and quantitative thematic analysis of 158 respondents to open invitations for petitions to the Scottish Parliament in 2017 and the Welsh Parliament in 2018, focused on prescribed psychotropic withdrawal, mostly antidepressants.
  • Accounts were unstructured in Scotland or prompted by four questions in Wales; analysis used a “lean thinking” approach to identify failure points, with themes generated until saturation and overlaid on two patient journey maps.
  • Thematic analysis was performed by AG, MB, and SL with additional support; only one researcher had personal experience of prescribed drug dependence and withdrawal and analysed 6% of the sample.

Limitations

  • Stated: the cohort was a self-selected sample of petition respondents, not a formal research study; demographic and treatment characteristics were not robustly captured, many responses were “not said,” and patients with negative experiences were probably more likely to respond, so the sample may represent more severe and protracted withdrawal than average.
  • Stated: there is possible confounding with benzodiazepines, z-drugs, and antipsychotics; some respondents were from outside the UK; and the long average duration of use (9.8 years) may relate to symptom severity.
  • Evident from the text: percentages are based only on respondents who addressed each item, so denominators vary and missing data are substantial; there was no independent clinical validation of withdrawal symptoms or of the alternative diagnoses reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/2045125320967183

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Patient Experiences of Prescribed Drug Dependence – Patient Journey Map: Initial Prescription and Outcomes.
Figure 1. Patient Experiences of Prescribed Drug Dependence – Patient Journey Map: Initial Prescription and Outcomes.CC BY-NC · PubMed Central
Figure 2. Patient Experiences of Prescribed Drug Dependence – Patient Journey Map: Withdrawal and Outcomes.
Figure 2. Patient Experiences of Prescribed Drug Dependence – Patient Journey Map: Withdrawal and Outcomes.CC BY-NC · PubMed Central

Verification

Claims the paper makes

13 Valid · 2 Not valid · 29 Not checked · 61 Own results and interpretations

47 more claims · 7 with their cited sources checked

Create a free account to see all 105 claims and to verify the 50 references still open.

See all claims — free account
  • It may state two separate claims as one. 44
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 54 references

Research works printed but not linked: 2

  1. Royal College of Psychiatrists. Position statement on antidepressants and depression. London: Royal College of Psychiatrists, 2019.
  2. National Institute for Health and Care Excellence. Depression in adults: recognition and management. (NICE Guideline 90). London: NICE, 2009. 31990491

Cited by

Metadata

Authors
Guy, A., Brown, M., Lewis, S., & Horowitz, M.
Affiliations
  • Psychotherapist, Secretariat Co-ordinator for the All-Party Parliamentary Group for Prescribed Drug Dependence, Basingstoke, Hampshire, UK
  • Retired Psychotherapist and Co-Founder of a Patient Support Group ‘Recovery and Renewal’, Helensburgh, UK
  • Lived Experience of Prescribed Drug Dependence, Cardiff, UK
  • University College London (GB)
Corresponding author
Guy, Anne
Venue
Therapeutic Advances in Psychopharmacology
Published
2020-01
Volume
10
Pages
2045125320967183-2045125320967183
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W3106367973
Cited by
77
References
56
Citations by year
2026: 8 · 2025: 12 · 2024: 16 · 2023: 14 · 2022: 11 · 2021: 16
FWCI
6.16
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
National Institute for Health and Care Research (ACF-2020-18-022)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Health Sciences › Health Professions › General Health Professions › Patient-Provider Communication in Healthcare
Keywords
antidepressant withdrawal symptoms, antidepressant discontinuation, patient experience, misdiagnosis, relapse, medication tapering, informed consent, NICE guidelines, polypharmacy, benzodiazepines, online forums, patient feedback, non-pharmacological treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.